Dianthus Therapeutics Ownership 2024 | Who Owns Dianthus Therapeutics Now?


OverviewFinancialsChart

Institutional Ownership

47.38%

Insider Ownership

2.23%

Retail Ownership

50.40%

Institutional Holders

42.00

Dianthus Therapeutics Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
FIDUCIARY TRUST CO----30,555-100.00%-Sep 30, 2023
WELLS FARGO & COMPANY/MN----779-100.00%-Sep 30, 2023
NORTHERN TRUST CORP----71,463-100.00%-Sep 30, 2023
CREDIT SUISSE AG/----149,300-100.00%-Sep 30, 2023
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----27,369-100.00%-Sep 30, 2023
MORGAN STANLEY----16,866-100.00%-Sep 30, 2023
ACADIAN ASSET MANAGEMENT LLC----457,690-100.00%-Sep 30, 2023
UMB BANK, N.A.----742-100.00%-Sep 30, 2023
ROYAL BANK OF CANADA----5,843-100.00%-Sep 30, 2023
HARBOR CAPITAL ADVISORS, INC.----167,454-100.00%-Sep 30, 2023
BESSEMER GROUP INC----237,292-100.00%-Sep 30, 2023
HARVARD MANAGEMENT CO INC----332,610-100.00%-Sep 30, 2023
BNP PARIBAS ARBITRAGE, SNC----4,474-100.00%-Sep 30, 2023
TWO SIGMA INVESTMENTS, LP----120,269-100.00%-Sep 30, 2023
GEODE CAPITAL MANAGEMENT, LLC----357,690-100.00%-Sep 30, 2023
CORSAIR CAPITAL MANAGEMENT, L.P.----100,000-100.00%-Sep 30, 2023
RATHBONES GROUP PLC----10,000-100.00%-Sep 30, 2023
BLACKROCK INC.----364,168-100.00%-Sep 30, 2023
CHEYNE CAPITAL MANAGEMENT (UK) LLP----47,170-100.00%-Sep 30, 2023
BANK OF NEW YORK MELLON CORP----60,404-100.00%-Sep 30, 2023

Dianthus Therapeutics's largest institutional shareholder is FIDUCIARY TRUST CO, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
FIDUCIARY TRUST CO----30,555-100.00%-Sep 30, 2023
WELLS FARGO & COMPANY/MN----779-100.00%-Sep 30, 2023
NORTHERN TRUST CORP----71,463-100.00%-Sep 30, 2023
CREDIT SUISSE AG/----149,300-100.00%-Sep 30, 2023
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----27,369-100.00%-Sep 30, 2023
MORGAN STANLEY----16,866-100.00%-Sep 30, 2023
ACADIAN ASSET MANAGEMENT LLC----457,690-100.00%-Sep 30, 2023
UMB BANK, N.A.----742-100.00%-Sep 30, 2023
ROYAL BANK OF CANADA----5,843-100.00%-Sep 30, 2023
HARBOR CAPITAL ADVISORS, INC.----167,454-100.00%-Sep 30, 2023
BESSEMER GROUP INC----237,292-100.00%-Sep 30, 2023
HARVARD MANAGEMENT CO INC----332,610-100.00%-Sep 30, 2023
BNP PARIBAS ARBITRAGE, SNC----4,474-100.00%-Sep 30, 2023
TWO SIGMA INVESTMENTS, LP----120,269-100.00%-Sep 30, 2023
GEODE CAPITAL MANAGEMENT, LLC----357,690-100.00%-Sep 30, 2023
CORSAIR CAPITAL MANAGEMENT, L.P.----100,000-100.00%-Sep 30, 2023
RATHBONES GROUP PLC----10,000-100.00%-Sep 30, 2023
BLACKROCK INC.----364,168-100.00%-Sep 30, 2023
CHEYNE CAPITAL MANAGEMENT (UK) LLP----47,170-100.00%-Sep 30, 2023
BANK OF NEW YORK MELLON CORP----60,404-100.00%-Sep 30, 2023

The largest Dianthus Therapeutics shareholder by % of total assets is FIDUCIARY TRUST CO. The company owns 0.00 shares of Dianthus Therapeutics (MGTA), representing 0.00% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC----50-100.00%-Sep 30, 2023
ALLWORTH FINANCIAL LP----375-100.00%-Sep 30, 2023
UMB BANK, N.A.----742-100.00%-Sep 30, 2023
WELLS FARGO & COMPANY/MN----779-100.00%-Sep 30, 2023
BNP PARIBAS ARBITRAGE, SNC----4,474-100.00%-Sep 30, 2023
ROYAL BANK OF CANADA----5,843-100.00%-Sep 30, 2023
RATHBONES GROUP PLC----10,000-100.00%-Sep 30, 2023
SOUND VIEW WEALTH ADVISORS GROUP, LLC----10,500-100.00%-Sep 30, 2023
UBS GROUP AG----11,177-100.00%-Sep 30, 2023
TOWER RESEARCH CAPITAL LLC (TRC)----12,190-100.00%-Sep 30, 2023
MORGAN STANLEY----16,866-100.00%-Sep 30, 2023
XTX TOPCO LTD----26,932-100.00%-Sep 30, 2023
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----27,369-100.00%-Sep 30, 2023
FIDUCIARY TRUST CO----30,555-100.00%-Sep 30, 2023
CHEYNE CAPITAL MANAGEMENT (UK) LLP----47,170-100.00%-Sep 30, 2023
BANK OF NEW YORK MELLON CORP----60,404-100.00%-Sep 30, 2023
NORTHERN TRUST CORP----71,463-100.00%-Sep 30, 2023
CORSAIR CAPITAL MANAGEMENT, L.P.----100,000-100.00%-Sep 30, 2023
TWO SIGMA INVESTMENTS, LP----120,269-100.00%-Sep 30, 2023
CREDIT SUISSE AG/----149,300-100.00%-Sep 30, 2023

As of Sep 30 2023, Dianthus Therapeutics's largest institutional buyer is INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC. The company purchased -50.00 stocks of MGTA, valued at -.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC----3,791,698-100.00%-Sep 30, 2023
ALPHABET INC.----3,339,138-100.00%-Sep 30, 2023
ACADIAN ASSET MANAGEMENT LLC----457,690-100.00%-Sep 30, 2023
BLACKROCK INC.----364,168-100.00%-Sep 30, 2023
GEODE CAPITAL MANAGEMENT, LLC----357,690-100.00%-Sep 30, 2023
HARVARD MANAGEMENT CO INC----332,610-100.00%-Sep 30, 2023
BESSEMER GROUP INC----237,292-100.00%-Sep 30, 2023
TWO SIGMA ADVISERS, LP----177,400-100.00%-Sep 30, 2023
HARBOR CAPITAL ADVISORS, INC.----167,454-100.00%-Sep 30, 2023
CREDIT SUISSE AG/----149,300-100.00%-Sep 30, 2023
TWO SIGMA INVESTMENTS, LP----120,269-100.00%-Sep 30, 2023
CORSAIR CAPITAL MANAGEMENT, L.P.----100,000-100.00%-Sep 30, 2023
NORTHERN TRUST CORP----71,463-100.00%-Sep 30, 2023
BANK OF NEW YORK MELLON CORP----60,404-100.00%-Sep 30, 2023
CHEYNE CAPITAL MANAGEMENT (UK) LLP----47,170-100.00%-Sep 30, 2023
FIDUCIARY TRUST CO----30,555-100.00%-Sep 30, 2023
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----27,369-100.00%-Sep 30, 2023
XTX TOPCO LTD----26,932-100.00%-Sep 30, 2023
MORGAN STANLEY----16,866-100.00%-Sep 30, 2023
TOWER RESEARCH CAPITAL LLC (TRC)----12,190-100.00%-Sep 30, 2023

As of Sep 30 2023, Dianthus Therapeutics's biggest institutional seller is ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC. The company sold -3.79M shares of MGTA, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC----3,791,698-100.00%-Sep 30, 2023
ALPHABET INC.----3,339,138-100.00%-Sep 30, 2023
ACADIAN ASSET MANAGEMENT LLC----457,690-100.00%-Sep 30, 2023
BLACKROCK INC.----364,168-100.00%-Sep 30, 2023
GEODE CAPITAL MANAGEMENT, LLC----357,690-100.00%-Sep 30, 2023
HARVARD MANAGEMENT CO INC----332,610-100.00%-Sep 30, 2023
BESSEMER GROUP INC----237,292-100.00%-Sep 30, 2023
TWO SIGMA ADVISERS, LP----177,400-100.00%-Sep 30, 2023
HARBOR CAPITAL ADVISORS, INC.----167,454-100.00%-Sep 30, 2023
CREDIT SUISSE AG/----149,300-100.00%-Sep 30, 2023
TWO SIGMA INVESTMENTS, LP----120,269-100.00%-Sep 30, 2023
CORSAIR CAPITAL MANAGEMENT, L.P.----100,000-100.00%-Sep 30, 2023
NORTHERN TRUST CORP----71,463-100.00%-Sep 30, 2023
BANK OF NEW YORK MELLON CORP----60,404-100.00%-Sep 30, 2023
CHEYNE CAPITAL MANAGEMENT (UK) LLP----47,170-100.00%-Sep 30, 2023
FIDUCIARY TRUST CO----30,555-100.00%-Sep 30, 2023
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----27,369-100.00%-Sep 30, 2023
XTX TOPCO LTD----26,932-100.00%-Sep 30, 2023
MORGAN STANLEY----16,866-100.00%-Sep 30, 2023
TOWER RESEARCH CAPITAL LLC (TRC)----12,190-100.00%-Sep 30, 2023
UBS GROUP AG----11,177-100.00%-Sep 30, 2023
SOUND VIEW WEALTH ADVISORS GROUP, LLC----10,500-100.00%-Sep 30, 2023
RATHBONES GROUP PLC----10,000-100.00%-Sep 30, 2023
ROYAL BANK OF CANADA----5,843-100.00%-Sep 30, 2023
BNP PARIBAS ARBITRAGE, SNC----4,474-100.00%-Sep 30, 2023
WELLS FARGO & COMPANY/MN----779-100.00%-Sep 30, 2023
UMB BANK, N.A.----742-100.00%-Sep 30, 2023
ALLWORTH FINANCIAL LP----375-100.00%-Sep 30, 2023
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC----50-100.00%-Sep 30, 2023

Dianthus Therapeutics's largest sold out institutional shareholder by shares sold is ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC, sold -3.79M shares, valued at -, as of undefined.

Dianthus Therapeutics Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
CORNERCAP GROUP OF FUNDS /VA/0.95%68,26333,91498.73%Sep 30, 2022
TEKLA LIFE SCIENCES INVESTORS0.20%114,141--Dec 31, 2023
Federated Hermes MDT Series0.16%400,248--Jan 31, 2024
ALGER FUNDS0.08%79,507--Jan 31, 2024
FIDELITY ADVISOR SERIES VII0.08%672,300--Jan 31, 2024
TEKLA HEALTHCARE INVESTORS0.07%78,290--Dec 31, 2023
BRIDGEWAY FUNDS INC0.06%150,000--Dec 29, 2023
VANGUARD VALLEY FORGE FUNDS0.05%24,259--Dec 31, 2023
Advantage Advisers Xanthus Fund, L.L.C.0.04%113,402--Mar 31, 2024
ACAP Strategic Fund0.02%251,066--Dec 31, 2023
UBS FUNDS0.02%75,005--Dec 31, 2023
ETFis Series Trust I0.01%18,703--Jan 31, 2024
Harbor ETF Trust0.01%57,473--Jan 31, 2024
DEUTSCHE DWS INVESTMENTS VIT FUNDS0.01%4,575--Dec 31, 2023
Harbor ETF Trust0.01%46,905--Jan 31, 2024
QUANTITATIVE MASTER SERIES LLC0.01%54,237--Dec 31, 2023
HARBOR FUNDS0.01%143,270--Jan 31, 2024
FIDELITY COMMONWEALTH TRUST0.01%18,523--Feb 29, 2024
FIRST TRUST EXCHANGE-TRADED FUND0.01%55,275--Dec 31, 2023
HARBOR FUNDS0.01%121,064--Jan 31, 2024
ALPS ETF Trust0.00%56,924--Feb 29, 2024
VANGUARD INDEX FUNDS0.00%1,897,129--Dec 31, 2023
TIAA SEPARATE ACCOUNT VA 10.00%683--Dec 31, 2023
FIDELITY SELECT PORTFOLIOS0.00%109,100--Feb 29, 2024
FIDELITY CONCORD STREET TRUST0.00%332,522--Feb 29, 2024
PRINCIPAL VARIABLE CONTRACTS FUNDS INC0.00%60,000--Dec 31, 2023
Federated Hermes Global Allocation Fund0.00%14,029--Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%33,990--Dec 31, 2023
Calvert Variable Products, Inc.0.00%1,719--Dec 31, 2023
SCHWAB CAPITAL TRUST0.00%27,369--Feb 29, 2024
GPS Funds I0.00%2,196--Dec 31, 2023
Voya VARIABLE PORTFOLIOS INC0.00%11,888--Dec 31, 2023
VANGUARD WORLD FUND0.00%87,864--Feb 29, 2024
STATE STREET VARIABLE INSURANCE SERIES FUNDS INC0.00%1,500--Dec 31, 2023
SunAmerica Specialty Series0.00%171--Apr 30, 2021
MUTUAL FUND SERIES TRUST0.00%1,000,000--Dec 31, 2023
TIAA-CREF LIFE FUNDS0.00%395--Dec 31, 2023
SA FUNDS INVESTMENT TRUST0.00%2,028--Dec 31, 2023
VARIABLE INSURANCE PRODUCTS FUND II0.00%1,288--Dec 31, 2023
FIDELITY SALEM STREET TRUST0.00%220,782--Feb 29, 2024
RUSSELL INVESTMENT FUNDS0.00%5,534--Dec 31, 2023
T. Rowe Price Index Trust, Inc.0.00%1,396--Feb 29, 2024
ProFunds0.00%640--Jan 31, 2024
RYDEX SERIES FUNDS0.00%285--Dec 31, 2023
STATE STREET INSTITUTIONAL INVESTMENT TRUST0.00%5,900--Dec 31, 2023
PRINCIPAL FUNDS, INC.0.00%423,521--Feb 29, 2024
PGIM ETF TRUST0.00%4,139--Feb 29, 2024
NATIONWIDE MUTUAL FUNDS0.00%7,090--Jan 31, 2024
VANGUARD SCOTTSDALE FUNDS0.00%103,505--Feb 29, 2024
PACE SELECT ADVISORS TRUST0.00%16,100--Jan 31, 2024
ALLIANZ VARIABLE INSURANCE PRODUCTS TRUST0.00%2,522--Dec 31, 2023
ADVANCED SERIES TRUST0.00%162,988--Dec 29, 2023
RYDEX DYNAMIC FUNDS0.00%159--Dec 31, 2023
VALIC Co I0.00%11,089--Feb 29, 2024
ALLSPRING MASTER TRUST0.00%2,187--Feb 29, 2024
Guggenheim Active Allocation Fund0.00%178--Feb 29, 2024
NATIONWIDE VARIABLE INSURANCE TRUST0.00%3,990--Dec 31, 2023
RYDEX VARIABLE TRUST0.00%29--Dec 31, 2023
PENN SERIES FUNDS INC0.00%600--Dec 29, 2023
MASTER INVESTMENT PORTFOLIO0.00%1,699--Dec 31, 2023
PROSHARES TRUST0.00%4,953--Feb 29, 2024
HC CAPITAL TRUST0.00%486--Dec 31, 2023
VANGUARD WELLINGTON FUND0.00%6,132--Feb 29, 2024
MORGAN STANLEY PATHWAY FUNDS0.00%1,217--Feb 29, 2024
LINCOLN VARIABLE INSURANCE PRODUCTS TRUST0.00%25,747--Dec 31, 2023
NORTHERN FUNDS0.00%10,083--Dec 29, 2023
SUNAMERICA SERIES TRUST0.00%3,299--Jan 31, 2024
COLLEGE RETIREMENT EQUITIES FUND0.00%9,114--Dec 31, 2023
EQ ADVISORS TRUST0.00%6,850--Dec 31, 2023
RUSSELL INVESTMENT CO0.00%1,508--Jan 31, 2024
Brighthouse Funds Trust II0.00%10,252--Dec 31, 2023
Principal Exchange-Traded Funds0.00%56--Mar 31, 2024
Advisors' Inner Circle Fund III0.00%53--Jan 31, 2024
AMERICAN CENTURY ETF TRUST0.00%370--Feb 29, 2024
PACIFIC SELECT FUND0.00%10,990--Dec 31, 2023
DFA INVESTMENT DIMENSIONS GROUP INC0.00%3,047--Jan 31, 2024
MASSMUTUAL SELECT FUNDS0.00%2,446--Dec 31, 2023
iSHARES TRUST0.00%19,872--Feb 29, 2024
BlackRock Variable Series Funds, Inc.0.00%3,568--Dec 31, 2023
Bridge Builder Trust0.00%4,565--Dec 31, 2023
BLACKROCK FUNDS0.00%2,524--Feb 29, 2024
SEI INSTITUTIONAL INVESTMENTS TRUST0.00%7,300--Feb 29, 2024
John Hancock Funds II0.00%3,863--Feb 29, 2024

Dianthus Therapeutics's largest mutual fund holder by % of total assets is "CORNERCAP GROUP OF FUNDS /VA/", owning 68.26K shares, compromising 0.95% of its total assets.

Dianthus Therapeutics Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
30 Jun, 2342-16.00%
31 Mar, 2350-3.85%
31 Dec, 2252-22.39%
30 Sep, 2267-4.29%
30 Jun, 2270-16.67%
31 Mar, 2284-6.67%
31 Dec, 2190-2.17%
30 Sep, 2192-1.08%
30 Jun, 21936.90%
31 Mar, 2187-1.14%
31 Dec, 2088-3.30%
30 Sep, 2091-3.19%
30 Jun, 209432.39%
31 Mar, 2071-5.33%
31 Dec, 19755.63%
30 Sep, 19714.41%
30 Jun, 19687.94%
31 Mar, 196321.15%
31 Dec, 18526.12%
30 Sep, 18492.08%
30 Jun, 1848-

As of 30 Jun 23, 42 institutions are holding Dianthus Therapeutics's shares, representing a decrease of -16.00% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
30 Jun, 2328,730,941-1.97%
31 Mar, 2329,308,0704.84%
31 Dec, 2227,955,148-39.79%
30 Sep, 2246,426,8002.28%
30 Jun, 2245,392,339-5.13%
31 Mar, 2247,847,7030.22%
31 Dec, 2147,741,32925.95%
30 Sep, 2137,903,6411.38%
30 Jun, 2137,388,5386.03%
31 Mar, 2135,261,2398.57%
31 Dec, 2032,479,3101.85%
30 Sep, 2031,887,793-2.05%
30 Jun, 2032,554,50818.40%
31 Mar, 2027,495,726-4.69%
31 Dec, 1928,848,0912.82%
30 Sep, 1928,057,059-1.39%
30 Jun, 1928,453,31314.97%
31 Mar, 1924,748,12012.41%
31 Dec, 1822,015,39862.44%
30 Sep, 1813,552,9290.14%
30 Jun, 1813,534,169-

Dianthus Therapeutics (MGTA) has 28.73M shares outstanding as of 30 Jun 23, down -1.97% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
30 Jun, 2347.38%2.03%
31 Mar, 2348.33%2.18%
31 Dec, 2247.08%0.77%
30 Sep, 2278.33%1.32%
30 Jun, 2277.18%1.17%
31 Mar, 2281.37%1.23%
31 Dec, 2181.21%1.94%
30 Sep, 2164.70%1.33%
30 Jun, 2169.62%1.32%
31 Mar, 2172.60%1.61%
31 Dec, 2067.17%1.54%
30 Sep, 2066.08%0.98%
30 Jun, 2082.18%1.68%
31 Mar, 2069.85%1.15%
31 Dec, 1977.94%1.49%
30 Sep, 1972.27%1.20%
30 Jun, 1977.61%1.42%
31 Mar, 1974.05%0.52%
31 Dec, 18119.72%2.20%
30 Sep, 1873.70%1.36%
30 Jun, 1873.60%-

As of 30 Jun 23, Dianthus Therapeutics is held by 47.38% institutional shareholders, representing a 2.03% growth compared to 31 Mar 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
30 Jun, 2313-45.83%
31 Mar, 23244.35%
31 Dec, 22234.55%
30 Sep, 2222-33.33%
30 Jun, 22333.13%
31 Mar, 2232-23.81%
31 Dec, 2142-8.70%
30 Sep, 2146-14.81%
30 Jun, 215442.11%
31 Mar, 2138-9.52%
31 Dec, 2042-12.50%
30 Sep, 2048-15.79%
30 Jun, 205767.65%
31 Mar, 2034-8.11%
31 Dec, 193715.63%
30 Sep, 1932-21.95%
30 Jun, 1941-
31 Mar, 194146.43%
31 Dec, 1828-9.68%
30 Sep, 1831-35.42%
30 Jun, 1848-

13 institutional shareholders have increased their position in MGTA stock as of 30 Jun 23 compared to 24 in the previous quarter (a -45.83% decrease).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
30 Jun, 231011.11%
31 Mar, 239-35.71%
31 Dec, 2214-41.67%
30 Sep, 222433.33%
30 Jun, 2218-35.71%
31 Mar, 222833.33%
31 Dec, 2121-12.50%
30 Sep, 212420.00%
30 Jun, 2120-28.57%
31 Mar, 212827.27%
31 Dec, 202237.50%
30 Sep, 2016-30.43%
30 Jun, 202327.78%
31 Mar, 2018-
31 Dec, 1918-
30 Sep, 1918100.00%
30 Jun, 19928.57%
31 Mar, 197-56.25%
31 Dec, 1816220.00%
30 Sep, 185-
30 Jun, 18--

10 institutional shareholders have reduced their position in MGTA stock as of 30 Jun 23 compared to 9 in the previous quarter (a 11.11% increase).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
30 Jun, 2342-16.00%28,730,941-1.97%47.38%2.03%13-45.83%1011.11%
31 Mar, 2350-3.85%29,308,0704.84%48.33%2.18%244.35%9-35.71%
31 Dec, 2252-22.39%27,955,148-39.79%47.08%0.77%234.55%14-41.67%
30 Sep, 2267-4.29%46,426,8002.28%78.33%1.32%22-33.33%2433.33%
30 Jun, 2270-16.67%45,392,339-5.13%77.18%1.17%333.13%18-35.71%
31 Mar, 2284-6.67%47,847,7030.22%81.37%1.23%32-23.81%2833.33%
31 Dec, 2190-2.17%47,741,32925.95%81.21%1.94%42-8.70%21-12.50%
30 Sep, 2192-1.08%37,903,6411.38%64.70%1.33%46-14.81%2420.00%
30 Jun, 21936.90%37,388,5386.03%69.62%1.32%5442.11%20-28.57%
31 Mar, 2187-1.14%35,261,2398.57%72.60%1.61%38-9.52%2827.27%
31 Dec, 2088-3.30%32,479,3101.85%67.17%1.54%42-12.50%2237.50%
30 Sep, 2091-3.19%31,887,793-2.05%66.08%0.98%48-15.79%16-30.43%
30 Jun, 209432.39%32,554,50818.40%82.18%1.68%5767.65%2327.78%
31 Mar, 2071-5.33%27,495,726-4.69%69.85%1.15%34-8.11%18-
31 Dec, 19755.63%28,848,0912.82%77.94%1.49%3715.63%18-
30 Sep, 19714.41%28,057,059-1.39%72.27%1.20%32-21.95%18100.00%
30 Jun, 19687.94%28,453,31314.97%77.61%1.42%41-928.57%
31 Mar, 196321.15%24,748,12012.41%74.05%0.52%4146.43%7-56.25%
31 Dec, 18526.12%22,015,39862.44%119.72%2.20%28-9.68%16220.00%
30 Sep, 18492.08%13,552,9290.14%73.70%1.36%31-35.42%5-
30 Jun, 1848-13,534,169-73.60%-48---

Dianthus Therapeutics Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Oct 03, 2023Fairmount Funds Management LLCdirector, 10 percent owner P-PurchaseBuy24,670$13.63$336.25K1,928,503
Sep 28, 2023Fairmount Funds Management LLCdirector, 10 percent owner P-PurchaseBuy30,000$13.15$394.50K1,903,833
Sep 25, 2023Randhawa Simratofficer Chief Medical OfficerP-PurchaseBuy2,000$13.20$26.40K4,000
Sep 25, 2023Randhawa Simratofficer Chief Medical OfficerP-PurchaseBuy2,000$13.20$26.40K2,000
Sep 21, 2023Fairmount Funds Management LLCdirector, 10 percent owner P-PurchaseBuy30,000$13.20$396.00K1,873,833
Sep 13, 2023Fairmount Funds Management LLCdirector, 10 percent owner P-PurchaseBuy9,367$11.76$110.16K1,843,833
Sep 13, 2023Fairmount Funds Management LLCdirector, 10 percent owner P-PurchaseBuy14,887$10.85$161.52K1,834,466

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Oct 03, 2023Fairmount Funds Management LLCdirector, 10 percent owner P-PurchaseBuy24,670$13.63$336.25K1,928,503
Sep 28, 2023Fairmount Funds Management LLCdirector, 10 percent owner P-PurchaseBuy30,000$13.15$394.50K1,903,833
Sep 25, 2023Randhawa Simratofficer Chief Medical OfficerP-PurchaseBuy2,000$13.20$26.40K4,000
Sep 25, 2023Randhawa Simratofficer Chief Medical OfficerP-PurchaseBuy2,000$13.20$26.40K2,000
Sep 21, 2023Fairmount Funds Management LLCdirector, 10 percent owner P-PurchaseBuy30,000$13.20$396.00K1,873,833
Sep 13, 2023Fairmount Funds Management LLCdirector, 10 percent owner P-PurchaseBuy9,367$11.76$110.16K1,843,833
Sep 13, 2023Fairmount Funds Management LLCdirector, 10 percent owner P-PurchaseBuy14,887$10.85$161.52K1,834,466

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Sep 13, 2023Soteropoulos Pauladirector-Sell28,792$8.44$243.00K-
Sep 13, 2023Garcia Marinodirector, officer CEO and PresidentSell182,659$6.70$1.22M-
Sep 13, 2023Garcia Marinodirector, officer CEO and PresidentSell326,004$8.44$2.75M-
Sep 13, 2023Randhawa Simratofficer Chief Medical OfficerSell95,974$8.44$810.02K-

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Oct 03, 2023Fairmount Funds Management LLCdirector, 10 percent owner P-PurchaseBuy24,670$13.63$336.25K1,928,503
Sep 28, 2023Fairmount Funds Management LLCdirector, 10 percent owner P-PurchaseBuy30,000$13.15$394.50K1,903,833
Sep 25, 2023Randhawa Simratofficer Chief Medical OfficerP-PurchaseBuy2,000$13.20$26.40K4,000
Sep 25, 2023Randhawa Simratofficer Chief Medical OfficerP-PurchaseBuy2,000$13.20$26.40K2,000
Sep 21, 2023Fairmount Funds Management LLCdirector, 10 percent owner P-PurchaseBuy30,000$13.20$396.00K1,873,833
Sep 13, 2023Meng Leidirector-A-AwardBuy6,500$11.20$72.80K6,500
Sep 13, 2023Meng Leidirector-Buy---1,217,554
Sep 13, 2023Violin Jonathandirector-A-AwardBuy6,500$11.20$72.80K6,500
Sep 13, 2023Fairmount Funds Management LLCdirector, 10 percent owner P-PurchaseBuy9,367$11.76$110.16K1,843,833
Sep 13, 2023Fairmount Funds Management LLCdirector, 10 percent owner P-PurchaseBuy14,887$10.85$161.52K1,834,466
Sep 13, 2023Fairmount Funds Management LLCdirector, 10 percent owner A-AwardBuy6,500$11.20$72.80K6,500
Sep 13, 2023Lawton Alison Francesdirector-A-AwardBuy6,500$11.20$72.80K6,500
Sep 13, 2023Soteropoulos Pauladirector-A-AwardBuy6,500$11.20$72.80K6,500
Sep 13, 2023McGeorge Annedirector-A-AwardBuy6,500$11.20$72.80K6,500
Sep 13, 2023MOULDER LEON O JRdirector-A-AwardBuy6,500$11.20$72.80K6,500
Sep 13, 2023Fairmount Funds Management LLCdirector, 10 percent owner Buy---1,819,579
Sep 13, 2023Soteropoulos Pauladirector-Sell28,792$8.44$243.00K-
Sep 13, 2023Garcia Marinodirector, officer CEO and PresidentSell182,659$6.70$1.22M-
Sep 13, 2023Garcia Marinodirector, officer CEO and PresidentSell326,004$8.44$2.75M-
Sep 13, 2023Randhawa Simratofficer Chief Medical OfficerSell95,974$8.44$810.02K-

The last insider sell of Dianthus Therapeutics's stock was made by Soteropoulos Paula on Sep 13 2023, selling 28,792 shares at $8.44 per share (valued at $243.00K). The last insider buy of MGTA was made by Fairmount Funds Management LLC on Oct 03 2023, buying 24,670 shares at $13.63 per share (worth $336.25K).

Dianthus Therapeutics Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q3 2023137185.71%
Q1 2023-2-
Q4 20225--
Q3 20229--
Q2 202219--
Q1 20228--
Q4 20211--
Q3 2021139144.44%
Q2 20211211200.00%
Q1 202151500.00%
Q4 20202728.57%
Q3 20201--
Q2 20201111100.00%
Q1 202065120.00%
Q4 201972429.17%
Q3 2019-7-
Q2 201994225.00%
Q1 201984200.00%
Q3 20181--
Q2 2018207327.40%

13 total buy trades, and 7 total sell trades (buy/sell ratio of 1.86%) were made by Dianthus Therapeutics's insiders, as of Q3 2023.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q3 20236--
Q1 2023-2-
Q4 2022---
Q3 2022---
Q2 2022---
Q1 2022---
Q4 2021---
Q3 2021-7-
Q2 2021---
Q1 2021---
Q4 2020---
Q3 2020---
Q2 20201--
Q1 2020-3-
Q4 2019-17-
Q3 2019-7-
Q2 2019-4-
Q1 2019-2-
Q3 2018---
Q2 20182--

As of Q3 2023, Insider owners conducted 6 open market buy trades and 0 open market sell trades of Dianthus Therapeutics's stocks.

Dianthus Therapeutics Peer Ownership


TickerCompany
SPROSpero Therapeutics, Inc.
TILInstil Bio, Inc.
NUVBNuvation Bio Inc.
NXTCNextCure, Inc.
CTMXCytomX Therapeutics, Inc.
ACHLAchilles Therapeutics plc
NLTXNeurogene Inc.
ASMBAssembly Biosciences, Inc.

MGTA Ownership FAQ


Dianthus Therapeutics is owned by institutional shareholders (47.38%), insiders (2.23%), and public (50.40%). The largest institutional shareholder of Dianthus Therapeutics is FIDUCIARY TRUST CO (0% of total shares) and the top mutual fund owner is CORNERCAP GROUP OF FUNDS /VA/ (0.95% of total shares).

Dianthus Therapeutics's major institutional shareholders are FIDUCIARY TRUST CO, WELLS FARGO & COMPANY/MN, NORTHERN TRUST CORP, CREDIT SUISSE AG/, and CHARLES SCHWAB INVESTMENT MANAGEMENT INC. The top five shareholders own together 0% of the company's share outstanding.

As of Jun 2023, there are 42 institutional shareholders of Dianthus Therapeutics.

FIDUCIARY TRUST CO owns 0 shares of Dianthus Therapeutics, representing 0% of the company's total shares outstanding, valued at $0 (as of Sep 2023).

As of Sep 2023, WELLS FARGO & COMPANY/MN holds 0 shares of Dianthus Therapeutics (MGTA), compromising 0% of the company, valued at $0.

NORTHERN TRUST CORP is the third largest holder of Dianthus Therapeutics. The company owns 0 of the company's shares outstanding (worth $0).